Ludwig researchers reveal the molecular mechanisms by which the immune system is activated against tumors treated with radiation
A team of researchers led by Ludwig Chicago's Yang-Xin Fu and Ralph Weichselbaum has uncovered the primary signaling mechanisms and cellular interactions that drive immune responses against tumors treated with radiotherapy. Published in the current issue of Immunity, their study suggests novel strategies for boosting the effectiveness of radiotherapy, and for combining it with therapies that harness the immune system to treat cancer.
"Much of the conversation about the mechanisms by which radiation kills cancer cells has historically focused on the damage it does to DNA," says Weichselbaum, co-director of the Ludwig Center at the University of Chicago. "But it has recently become increasingly clear that the immune system plays an important--perhaps central--role in destroying tumors subjected to radiotherapy. Our study shows how radiation, DNA damage and the immune response that follows are linked."
Fu, Weichselbaum and their colleagues report that dendritic cells--among the immune system's primary reconnaissance forces--play a central role in the phenomenon. Through studies conducted in mouse models and cell cultures, they show that a protein within these cells named STING is key to activating the immune response to irradiated tumors. STING links the detection of small fragments of DNA to their production of an immune factor known as interferon-β (IFN-β). This factor boosts the ability of dendritic cells to activate the immune system's killer T cells, which destroy cancer cells.
Dendritic cells cruise the body looking for signs of infection or disease, using a variety of biochemical sensors that recognize general molecular patterns associated with different types of pathogens. One such detector, an enzyme known as cGAS, is activated by fragments of double-stranded DNA. cGas is a sensor of viral DNA that also senses damaged DNA from irradiated cells, thereby drawing the immune system into the host response to anti-tumor radiation.
The researchers show that cGAS in dendritic cells gets activated by such DNA fragments--an event that in turn switches on STING. This initiates a cascade of biochemical signals that culminates in the production of IFN-β, which promotes the activation of killer T cells by dendritic cells.
"This seems to be a fairly specific response in the context of radiation," says Weichselbaum. "If you knock out the STING gene in mice, their tumor growth is similar to that of normal mice. But, in the knock-out mice, the tumors are far more resistant to radiation than the tumors of control mice.
The team's experiments show that the dendritic cells from these STING knock-out mice fail to activate killer T cells following tumor irradiation. That capability, they find, can be restored by the addition of IFN-β.
Similarly, dendritic cells from mice whose cGAS genes were shut down or knocked out also failed to activate anti-tumor T cells. The cells regained that ability when given a dose of the molecules produced by cGAS that switch on STING signaling. Importantly, when those STING-activating molecules were injected into the tumors of normal mice, the tumors became very sensitive to radiation.
"These findings could open the door to improving cancer therapy," says Weichselbaum. "Drugs that activate STING signaling or the induction of IFN-β could be used to boost the effects of radiotherapy on tumors. Those effects might be observed in chemotherapy as well, since it too causes significant DNA damage."
In the longer term, says Weichselbaum, such molecules could be combined with existing killer T cell-boosting immunotherapies or cancer vaccines and radiation treatment to generate potent, systemic immune responses against metastatic cancers. He and his colleagues will be assessing these possibilities in mice.
This study was supported by the US National Institutes of Health, Ludwig Cancer Research and The Foglia Foundation.
About Ludwig Cancer Research
Ludwig Cancer Research is an international collaborative network of acclaimed scientists with a 40-year legacy of pioneering cancer discoveries. Ludwig combines basic research with the ability to translate its discoveries and conduct clinical trials to accelerate the development of new cancer diagnostics and therapies. Since 1971, Ludwig has invested more than $2.5 billion in life-changing cancer research through the not-for-profit Ludwig Institute for Cancer Research and the six U.S.-based Ludwig Centers.
For further information please contact Rachel Steinhardt, email@example.com or +1-646-371-7394.
Rachel Steinhardt | EurekAlert!
Study suggests possible new target for treating and preventing Alzheimer's
02.12.2016 | Oregon Health & Science University
The first analysis of Ewing's sarcoma methyloma opens doors to new treatments
01.12.2016 | IDIBELL-Bellvitge Biomedical Research Institute
A multi-institutional research collaboration has created a novel approach for fabricating three-dimensional micro-optics through the shape-defined formation of porous silicon (PSi), with broad impacts in integrated optoelectronics, imaging, and photovoltaics.
Working with colleagues at Stanford and The Dow Chemical Company, researchers at the University of Illinois at Urbana-Champaign fabricated 3-D birefringent...
In experiments with magnetic atoms conducted at extremely low temperatures, scientists have demonstrated a unique phase of matter: The atoms form a new type of quantum liquid or quantum droplet state. These so called quantum droplets may preserve their form in absence of external confinement because of quantum effects. The joint team of experimental physicists from Innsbruck and theoretical physicists from Hannover report on their findings in the journal Physical Review X.
“Our Quantum droplets are in the gas phase but they still drop like a rock,” explains experimental physicist Francesca Ferlaino when talking about the...
The Max Planck Institute for Physics (MPP) is opening up a new research field. A workshop from November 21 - 22, 2016 will mark the start of activities for an innovative axion experiment. Axions are still only purely hypothetical particles. Their detection could solve two fundamental problems in particle physics: What dark matter consists of and why it has not yet been possible to directly observe a CP violation for the strong interaction.
The “MADMAX” project is the MPP’s commitment to axion research. Axions are so far only a theoretical prediction and are difficult to detect: on the one hand,...
Broadband rotational spectroscopy unravels structural reshaping of isolated molecules in the gas phase to accommodate water
In two recent publications in the Journal of Chemical Physics and in the Journal of Physical Chemistry Letters, researchers around Melanie Schnell from the Max...
The efficiency of power electronic systems is not solely dependent on electrical efficiency but also on weight, for example, in mobile systems. When the weight of relevant components and devices in airplanes, for instance, is reduced, fuel savings can be achieved and correspondingly greenhouse gas emissions decreased. New materials and components based on gallium nitride (GaN) can help to reduce weight and increase the efficiency. With these new materials, power electronic switches can be operated at higher switching frequency, resulting in higher power density and lower material costs.
Researchers at the Fraunhofer Institute for Solar Energy Systems ISE together with partners have investigated how these materials can be used to make power...
16.11.2016 | Event News
01.11.2016 | Event News
14.10.2016 | Event News
02.12.2016 | Medical Engineering
02.12.2016 | Agricultural and Forestry Science
02.12.2016 | Physics and Astronomy